– SOUTH KOREA, Daejeon / USA, MA – Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders to treat cancer, today announced the appointment of David Main to its Board of Directors.
About David Main
David Main is a highly experienced biopharmaceutical executive who has more than 30 years of industry leadership experience with a strong track record of value creation and company growth.
Mr. Main is President and CEO of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he co-founded in 2006, Mr. Main oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a Nasdaq-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Before his leadership of Aquinox, Mr. Main served as President and CEO of INEX Pharmaceuticals and as a VP of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C.
“Orum’s Antibody neoDegrader Conjugate platform combines the strengths of targeted protein degraders and antibody-drug conjugates with a diversity of payloads needed to deliver precise tumor-killing action. I look forward to working with the Orum team and Board as the Company advances these innovative first-in-class tumor-directed targeted protein degraders into the clinic to improve the treatment of cancer,” commented David Main.
He received a BSc in pharmacy and an MBA from the University of British Columbia.
About Orum Therapeutics
Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD2 approach to provide dual precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD2 approach include the Antibody neoDegrader Conjugate platform, which generates first-in-class antibody-drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, and Daejeon, South Korea.
Orum’s Antibody neoDegrader Conjugate platform is built on novel targeted protein degrader combined with the precise tumor cell delivery mechanisms of antibodies to generate innovative, first-in-class cell-specific TPD for the treatment of cancer. The company has developed new molecular glue degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, neoDegraders are designed to be delivered specifically to cancer cells and degrade the intracellular target protein and cause tumor cell death.
For more information: https://www.orumrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.